FOXP1 and diabetic kidney disease: Zhang’s study concluded that CASC2 upregulation suppressed high glucose-induced proliferation, oxidative stress of human mesangial cells and extracellular matrix accumulation through miR-133b/FOXP1 regulatory pathway, suggesting that CASC2 was a novel biomarker for diabetic nephropathy treatment [34].